TITLE:
Chronic Refractory Idiopathic Urticaria
AUTHORS:
Indira Acharya, Ashik Pokharel, Ashbina Pokharel, Lanaya Williams Smith
KEYWORDS:
Omalizumab, Biological Agent, Chronic Spontaneous Urticaria (CSU), Conventional Treatment, Relapse
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.11 No.11,
November
2,
2023
ABSTRACT: Background: Chronic spontaneous urticaria (CSU) is a complex medical condition characterized by substantial morbidity and a negative impact on one’s quality of life. There are several treatment approaches available, tailored to the severity of the condition, which can enhance overall quality of life. Aim: In this article, we outline a systematic approach to managing chronic urticaria, while also elucidating the available treatment strategies for cases that prove resistant to conventional therapies. To illustrate our points, we present a clinical case as a practical example. Case Presentation: Here, we present a patient with CSU since childhood who presented in the context of refractory hives and generalized arthralgia that responded well to omalizumab therapy with no further relapse. Conclusion: Omalizumab is a biological agent that offers a potential treatment option for CSU. It is available for individuals twelve years and older who have not responded well to conventional treatments. It has demonstrated good efficacy with a relatively low rate of clinically significant adverse effects. Nonetheless, there is a dearth of research regarding the optimal method for tapering the dosage and determining the duration of treatment.